Vanguard Group Inc Bio Affinity Technologies, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 260,869 shares of BIAF stock, worth $247,825. This represents 0.0% of its overall portfolio holdings.
Number of Shares
260,869
Previous 171,994
51.67%
Holding current value
$247,825
Previous $371,000
46.09%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BIAF
# of Institutions
15Shares Held
468KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA87.2KShares$82,8210.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$26,4900.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC20KShares$19,0000.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$16,7200.0% of portfolio
-
Northern Trust Corp Chicago, IL13.7KShares$12,9780.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $2.59M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...